---
title: "3 numbers that explain Bristol Myers Squibb's dirt cheap valuation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300421147.md"
description: "With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff."
datetime: "2026-09-29T10:41:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300421147.md)
  - [en](https://longbridge.com/en/news/300421147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300421147.md)
generator: "portal-rs"
---

# 3 numbers that explain Bristol Myers Squibb's dirt cheap valuation

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb secures expanded US approval for Camzyos](https://longbridge.com/en/news/300671144.md)
- [Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma](https://longbridge.com/en/news/300139167.md)
- [Bristol Myers Squibb (BMY) Doubles MRD‑Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM](https://longbridge.com/en/news/300139432.md)
- [FACTBOX-US drugmakers turn to China for licensing deals](https://longbridge.com/en/news/300320607.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**